PortalPublikationenPrognostic, predictive and potential surrogate markers in ca...

Prognostic, predictive and potential surrogate markers in castration-resistant prostate cancer

Standard

Prognostic, predictive and potential surrogate markers in castration-resistant prostate cancer. / Aziz, Atiqullah; Kempkensteffen, Carsten; May, Matthias; Lebentrau, Steffen; Burger, Maximilian; Chun, Felix K-H; Brookman-May, Sabine.

in: EXPERT REV ANTICANC, Jahrgang 15, Nr. 6, 06.2015, S. 649-66.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Aziz, A, Kempkensteffen, C, May, M, Lebentrau, S, Burger, M, Chun, FK-H & Brookman-May, S 2015, 'Prognostic, predictive and potential surrogate markers in castration-resistant prostate cancer', EXPERT REV ANTICANC, Jg. 15, Nr. 6, S. 649-66. https://doi.org/10.1586/14737140.2015.1038247

APA

Aziz, A., Kempkensteffen, C., May, M., Lebentrau, S., Burger, M., Chun, F. K-H., & Brookman-May, S. (2015). Prognostic, predictive and potential surrogate markers in castration-resistant prostate cancer. EXPERT REV ANTICANC, 15(6), 649-66. https://doi.org/10.1586/14737140.2015.1038247

Vancouver

Aziz A, Kempkensteffen C, May M, Lebentrau S, Burger M, Chun FK-H et al. Prognostic, predictive and potential surrogate markers in castration-resistant prostate cancer. EXPERT REV ANTICANC. 2015 Jun;15(6):649-66. https://doi.org/10.1586/14737140.2015.1038247

Bibtex

@article{3550d81c924945beb9f0b486aca906ce,
title = "Prognostic, predictive and potential surrogate markers in castration-resistant prostate cancer",
abstract = "Several novel therapeutic agents have demonstrated improvement of overall survival and further patient relevant endpoints in the setting of castration-resistant prostate cancer. Nevertheless, two questions have become increasingly relevant: are there any prognostic or predictive markers that could ease clinical decision-making using risk stratification and risk-adapted treatment in order to provide a benefit for the patient? Furthermore, against the background of increasing possibilities of therapy sequencing in clinical practice and in the clinical trial landscape in castration-resistant prostate cancer, does an isolated evaluation of overall survival reliably mirror the benefit attributable to a single compound? To address both these questions, suitable parameters serving as surrogates for intermediate and long-term endpoints and reflecting individual benefit, respectively, need to be identified and proven.",
keywords = "Antineoplastic Agents, Biomarkers, Tumor, Endpoint Determination, Humans, Male, Prognosis, Prostatic Neoplasms, Castration-Resistant, Risk Assessment, Survival Rate, Journal Article, Review",
author = "Atiqullah Aziz and Carsten Kempkensteffen and Matthias May and Steffen Lebentrau and Maximilian Burger and Chun, {Felix K-H} and Sabine Brookman-May",
year = "2015",
month = jun,
doi = "10.1586/14737140.2015.1038247",
language = "English",
volume = "15",
pages = "649--66",
journal = "EXPERT REV ANTICANC",
issn = "1473-7140",
publisher = "Expert Reviews Ltd.",
number = "6",

}

RIS

TY - JOUR

T1 - Prognostic, predictive and potential surrogate markers in castration-resistant prostate cancer

AU - Aziz, Atiqullah

AU - Kempkensteffen, Carsten

AU - May, Matthias

AU - Lebentrau, Steffen

AU - Burger, Maximilian

AU - Chun, Felix K-H

AU - Brookman-May, Sabine

PY - 2015/6

Y1 - 2015/6

N2 - Several novel therapeutic agents have demonstrated improvement of overall survival and further patient relevant endpoints in the setting of castration-resistant prostate cancer. Nevertheless, two questions have become increasingly relevant: are there any prognostic or predictive markers that could ease clinical decision-making using risk stratification and risk-adapted treatment in order to provide a benefit for the patient? Furthermore, against the background of increasing possibilities of therapy sequencing in clinical practice and in the clinical trial landscape in castration-resistant prostate cancer, does an isolated evaluation of overall survival reliably mirror the benefit attributable to a single compound? To address both these questions, suitable parameters serving as surrogates for intermediate and long-term endpoints and reflecting individual benefit, respectively, need to be identified and proven.

AB - Several novel therapeutic agents have demonstrated improvement of overall survival and further patient relevant endpoints in the setting of castration-resistant prostate cancer. Nevertheless, two questions have become increasingly relevant: are there any prognostic or predictive markers that could ease clinical decision-making using risk stratification and risk-adapted treatment in order to provide a benefit for the patient? Furthermore, against the background of increasing possibilities of therapy sequencing in clinical practice and in the clinical trial landscape in castration-resistant prostate cancer, does an isolated evaluation of overall survival reliably mirror the benefit attributable to a single compound? To address both these questions, suitable parameters serving as surrogates for intermediate and long-term endpoints and reflecting individual benefit, respectively, need to be identified and proven.

KW - Antineoplastic Agents

KW - Biomarkers, Tumor

KW - Endpoint Determination

KW - Humans

KW - Male

KW - Prognosis

KW - Prostatic Neoplasms, Castration-Resistant

KW - Risk Assessment

KW - Survival Rate

KW - Journal Article

KW - Review

U2 - 10.1586/14737140.2015.1038247

DO - 10.1586/14737140.2015.1038247

M3 - SCORING: Journal article

C2 - 25905802

VL - 15

SP - 649

EP - 666

JO - EXPERT REV ANTICANC

JF - EXPERT REV ANTICANC

SN - 1473-7140

IS - 6

ER -